


## Analysis of Mirtazapine

(Under the Condition of USP41-NF36, Mirtazapine)

### Standard solution of Assay



### Conditions

|                        |   |                                     |                    |
|------------------------|---|-------------------------------------|--------------------|
| <b>System</b>          | : GL7700 HPLC system  | <b>Analyte:</b>                     |                    |
| <b>Column</b>          | : InertSustain C18 (5 $\mu$ m, 250 x 4.6 mm I.D.)                         | 1. Mirtazapine                      | 300 mg/L           |
| <b>Column Cat. No.</b> | : 5020-07346  |                                     |                    |
| <b>Eluent</b>          | : CH <sub>3</sub> CN/CH <sub>3</sub> OH/THF/Buffer* = 15/12.5/7.5/65, v/v |                                     |                    |
| <b>Flow rate</b>       | : 1.5 mL/min  |                                     |                    |
| <b>Col. Temp.</b>      | : 40 °C   | Theoretical plates (1)              | : 14,327 (> 7,000) |
| <b>Detection</b>       | : UV 290 nm (UV7750 UV Detector)  | Symmetry factor (1)                 | : 1.01 (< 2.0)     |
| <b>Injection Vol.</b>  | : 10 $\mu$ L  | RSD of the peak area of 1 (%) (n=6) |                    |
| <b>Sample</b>          | : Standard  |                                     | : 0.05 (< 1.0)     |

\* Dissolve 18 g of tetramethylammonium hydroxide pentahydrate in 950 mL of water.  
Adjust with phosphoric acid to a pH of 7.4. Dilute with water to 1 L.